Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Krishnaswami Vijayaraghavan

Cardiovascular Disease Scottsdale, AZ Medical Doctor

NPI 1376598151 CMS profile 17282

3099 N Civic Center Plz, Scottsdale, AZ 85251

Open in the dashboard

General payments

$927,310

865 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krishnaswami Vijayaraghavan of Scottsdale, AZ is reported in the CMS Open Payments database as having received $927,310 across 865 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,719 21
2024 General $105,828 118
2023 General $103,140 99
2022 General $157,140 111
2021 General $171,726 120
2020 General $155,669 142
2019 General $215,089 254

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krishnaswami Vijayaraghavan
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Krishnaswami Vijayaraghavan were reported at $18,719. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Krishnaswami Vijayaraghavan Cardiovascular Disease median Middle half National median
2019 $215,089 $450 $127–$1,392 $163
2020 $155,669 $242 $77–$751 $114
2021 $171,726 $335 $101–$1,037 $132
2022 $157,140 $395 $121–$1,211 $149
2023 $103,140 $443 $136–$1,283 $160
2024 $105,828 $450 $136–$1,323 $164
2025 $18,719 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $231,626 138 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $114,609 122 payments
  3. AstraZeneca Pharmaceuticals LP $102,777 130 payments
  4. Lilly USA, LLC $101,713 80 payments
  5. Amarin Pharma Inc. $78,679 74 payments
  6. Lexicon Pharmaceuticals, Inc. $75,428 71 payments
  7. Pfizer Inc. $56,819 50 payments
  8. Kiniksa Pharmaceuticals International, plc $31,693 35 payments
  9. Eli Lilly and Company $30,600 11 payments
  10. Kiniksa Pharmaceuticals, Ltd. $21,788 20 payments
  11. Other $81,577 134 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $687,758 254 payments
  2. Consulting Fee $86,056 29 payments
  3. Travel and Lodging $67,839 272 payments
  4. Honoraria $65,520 13 payments
  5. Food and Beverage $20,111 287 payments
  6. Education $27 10 payments
Products named General payments · program years 2019–2025
  1. Ozempic $176,305 102 payments
  2. JARDIANCE Diabetes $112,967 112 payments
  3. JARDIANCE Diabetes $106,770 76 payments
  4. FARXIGA $85,497 100 payments
  5. Inpefa $75,428 71 payments
  6. VYNDAQEL $55,866 47 payments
  7. Arcalyst $53,204 52 payments
  8. Vascepa Hypertriglyceridemia $47,513 46 payments
  9. RYBELSUS $37,566 23 payments
  10. Vascepa Cardiovascular $31,166 28 payments
  11. Other $115,841 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

865 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record